4basebio (LON:4BB) Trading 4.8% Higher – Still a Buy?

4basebio PLC (LON:4BB) shares traded up 4.8% during trading on Wednesday . The stock traded as high as GBX 496.80 and last traded at GBX 496.80. 242 shares were traded during mid-day trading, a decline of 85% from the average session volume of 1,596 shares. The stock had previously closed at GBX 474.

4basebio Price Performance

The company has a market capitalization of £76.93 million, a P/E ratio of -5.02 and a beta of 1.09. The stock’s fifty day simple moving average is GBX 540.23 and its 200-day simple moving average is GBX 644.66. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52.

Insider Buying and Selling

In other news, insider Amy Walker bought 2,650 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The shares were acquired at an average cost of GBX 586 per share, with a total value of £15,529. Also, insider Heikki Lanckriet bought 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 10th. The shares were purchased at an average cost of GBX 576 per share, for a total transaction of £17,280. In the last 90 days, insiders acquired 6,650 shares of company stock valued at $3,865,900. Insiders own 12.07% of the company’s stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.